{"news_desk": "Letters", "print_page": "26", "section_name": "Opinion", "subsection_name": null, "byline": [], "abstract": null, "type_of_material": "Letter", "word_count": "381", "lead_paragraph": "The F.D.A. and Kids v. Cancer discuss the agency\u2019s decision to approve the drug for use in children.", "pub_date": "2015-09-26T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "OxyContin and Children: The F.D.A. Responds", "content_kicker": "Letters", "print_headline": "OxyContin and Children: The F.D.A. Responds", "kicker": "Letters"}, "snippet": "The F.D.A. and Kids v. Cancer discuss the agency\u2019s decision to approve the drug for use in children.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/09/26/opinion/oxycontin-and-children-the-fda-responds.html", "keywords": [{"rank": "1", "is_major": "N", "value": "OxyContin (Drug)", "name": "subject"}, {"rank": "2", "is_major": "N", "value": "Food and Drug Administration", "name": "organizations"}], "blog": [], "_id": "5605d31f38f0d809f2db1f18", "source": "The New York Times"}